Literature DB >> 29914948

Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.

Anne Fournier1,2, Sylvain Goutelle3,4, Yok-Ai Que5, Philippe Eggimann6, Olivier Pantet6, Farshid Sadeghipour1,2, Pierre Voirol1,2, Chantal Csajka7.   

Abstract

The objective of this study was to investigate the population pharmacokinetics (PK) of amoxicillin in ICU burn patients and the optimal dosage regimens. This was a prospective study involving 21 consecutive burn patients receiving amoxicillin. PK data were analyzed using nonlinear mixed-effects modeling. Monte-Carlo simulations assessed the influence of various amoxicillin dosage regimens with identified covariates on the probability to achieve a target (PTA) value of time during which free amoxicillin concentrations in plasma exceeded the MIC (fT>MIC). A two-compartment model best described the data. Creatinine clearance (CLCR) and body weight (BW) influenced amoxicillin CL and central volume of distribution (V1), respectively. The median CLCR (Cockcroft-Gault formula) was high (128 ml/min), with 25% of patients having CLCRs of >150 ml/min. The CL, V1, and half-life (t1/2) values at steady state for a patient with a CLCR of 110 ml/min and BW of 70 kg were 13.6 liters/h, 9.7 liters, and 0.8 h, respectively. Simulations showed that a target fT>MIC of ≥50% was achieved (PTA > 90%) with standard amoxicillin dosage regimens (1 to 2 g every 6 to 8 h [q6-8h]) when the MIC was low (<1 mg/liter). However, increased dosages of up to 2 g/4 h were necessary in patients with augmented CLRs or higher MICs. Prolonging amoxicillin infusion from 30 min to 2 h had a favorable effect on target attainment. In conclusion, this population analysis shows an increased amoxicillin CL and substantial CL PK variability in burn patients compared to literature data with nonburn patients. Situations of augmented CLCR and/or high bacterial MIC target values may require dosage increases and longer infusion durations. (This study has been registered at ClinicalTrials.gov under identifier NCT01965340.).
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  amoxicillin; burn patients; pharmacokinetics; population pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 29914948      PMCID: PMC6125536          DOI: 10.1128/AAC.00505-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  54 in total

1.  Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.

Authors:  Mieke Carlier; Michaël Noë; Jan J De Waele; Veronique Stove; Alain G Verstraete; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2013-06-25       Impact factor: 5.790

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 3.  Whole-body inflammation in trauma patients. An autopsy study.

Authors:  H K Nuytinck; X J Offermans; K Kubat; J A Goris
Journal:  Arch Surg       Date:  1988-12

4.  Amoxicillin Crystalluria, an Emerging Complication with an Old and Well-Known Antibiotic.

Authors:  Valérie Zeller; Déborah Puyraimond-Zemmour; Thomas Sené; Olivier Lidove; Vanina Meyssonnier; Jean-Marc Ziza
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 5.  Pharmacokinetics of antibiotics in burn patients.

Authors:  M J Weinbren
Journal:  J Antimicrob Chemother       Date:  1999-09       Impact factor: 5.790

6.  Use of high-performance liquid chromatography (HPLC) to monitor beta-lactam plasma concentrations during the treatment of endocarditis.

Authors:  P Tattevin; O Tribut; C Arvieux; M Dupont; R Flicoteaux; L Desbordes; Y Le Tulzo; C Michelet
Journal:  Clin Microbiol Infect       Date:  2005-01       Impact factor: 8.067

7.  Generalized vascular permeability and pulmonary function in patients following serious trauma.

Authors:  P Gosling; K Sanghera; G Dickson
Journal:  J Trauma       Date:  1994-04

8.  Cause of death and correlation with autopsy findings in burns patients.

Authors:  P Krishnan; Q Frew; A Green; R Martin; P Dziewulski
Journal:  Burns       Date:  2012-11-06       Impact factor: 2.744

Review 9.  How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors:  Gloria Wong; Fekade Bruck Sime; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  1 in total

1.  Suitability of Amoxicillin-Clavulanic Acid for Administration via Prolonged Infusion.

Authors:  Sarah Fawaz; Breanna Dixon; Stephen Barton; Amna Mohamed; Shereen Nabhani-Gebara
Journal:  Drug Des Devel Ther       Date:  2020-01-10       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.